Liminatus Pharma ( (LIMN) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Liminatus Pharma has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The primary reason for this delay is the inability to complete financial statements in time to secure the necessary reviews and signatures. The company anticipates that the report will be filed within five calendar days following the original due date. Liminatus Pharma does not expect any significant changes in its financial results compared to the previous fiscal year. The company remains committed to compliance, with CEO Chris Kim signing off on the notification.
More about Liminatus Pharma
Average Trading Volume: 44,798
Technical Sentiment Signal: Sell
Current Market Cap: $46.46M
Find detailed analytics on LIMN stock on TipRanks’ Stock Analysis page.